Decoy Therapeutics annual capital expenditures (capex)
2014
2015
2016
2017
2018
2019
2020
2021
2022
2024
2025
Decoy Therapeutics Capital Expenditures (CapEx) Growth & History (DCOY)
Decoy Therapeutics's capital expenditures (capex) was $577,000 for fiscal 2025.
View full Decoy Therapeutics company overviewDecoy Therapeutics annual capital expenditures (capex) history
| Fiscal year | Period ended | Capital expenditures (CapEx) | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $577,000 | $577,000 | — |
| 2024 | 2024-12-31 | $0 | — | — |
| 2022 | 2022-12-31 | $1.5M | $1.5M | — |
| 2021 | 2021-12-31 | $0 | −$2,600 | — |
| 2020 | 2020-12-31 | $2,600 | $2,600 | — |
| 2019 | 2019-12-31 | $0 | $0 | — |
| 2018 | 2018-12-31 | $0 | −$113,498 | — |
| 2017 | 2017-12-31 | $113,498 | −$445,880 | −79.71% |
| 2016 | 2016-12-31 | $559,378 | $293,761 | +110.60% |
| 2015 | 2015-12-31 | $265,617 | $189,476 | +248.85% |
| 2014 | 2014-12-31 | $76,141 | — | — |
Decoy Therapeutics quarterly capital expenditures (capex)
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
| Fiscal quarter | Period ended | Capital expenditures (CapEx) | Change | YoY change |
|---|---|---|---|---|
| Q4 2018 | 2018-12-31 | $0 | −$15,398 | — |
| Q3 2018 | 2018-09-30 | $0 | −$44,359 | — |
| Q2 2018 | 2018-06-30 | $0 | −$31,591 | — |
| Q1 2018 | 2018-03-31 | $0 | −$22,150 | — |
| Q4 2017 | 2017-12-31 | $15,398 | −$34,993 | −69.44% |
| Q3 2017 | 2017-09-30 | $44,359 | −$174,426 | −79.72% |
| Q2 2017 | 2017-06-30 | $31,591 | −$151,325 | −82.73% |
| Q1 2017 | 2017-03-31 | $22,150 | −$85,136 | −79.35% |
| Q4 2016 | 2016-12-31 | $50,391 | $8,039 | +18.98% |
| Q3 2016 | 2016-09-30 | $218,785 | $71,082 | +48.12% |
| Q2 2016 | 2016-06-30 | $182,916 | $133,749 | +272.03% |
| Q1 2016 | 2016-03-31 | $107,286 | $80,891 | +306.46% |
| Q4 2015 | 2015-12-31 | $42,352 | — | — |
| Q3 2015 | 2015-09-30 | $147,703 | — | — |
| Q2 2015 | 2015-06-30 | $49,167 | — | — |
| Q1 2015 | 2015-03-31 | $26,395 | — | — |
Decoy Therapeutics capital expenditures (capex) trends
Over the last five fiscal years, Decoy Therapeutics's capital expenditures (capex) increased from $2,600 to $577,000, a change of $574,400. The latest reported quarter, Q4 2018, shows $0.
About the metric
What capital expenditures (CapEx) mean
Capital expenditures, commonly called CapEx, are cash investments in long-lived assets such as property, plants, equipment, infrastructure, and productive software. CapEx can support future growth or maintain existing operations, but it reduces current-period free cash flow.
Calculation and source
SEC-reported capital expenditures
TickerStat standardizes cash payments for property, plant, equipment, and other productive assets reported in company SEC filings. When a filer reports separate qualifying CapEx components instead of a total, those components are combined for the same fiscal period. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Decoy Therapeutics source filings ↗